The US Food and Drug Administration’s (FDA) top neuroscience official, Billy Dunn, who oversaw the controversial approval of Biogen’s Alzheimer’s disease drug Aduhelm (aducanumab-avwa), is leaving the ...
Three papers published as Viewpoints in JAMA Internal Medicine this week highlight the rationale provided by the US Food and Drug Administration (FDA) on the agency’s approval of aducanumab (Aduhelm; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results